Juan Andres - 22 Oct 2021 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Technical Operations and Quality Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
22 Oct 2021
Transactions value $
-$6,330,842
Form type
4
Filing time
26 Oct 2021, 17:13:14
Previous filing
22 Oct 2021
Next filing
29 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $61.1K +5K $12.21* 5K 22 Oct 2021 Direct F1
transaction MRNA Common Stock Sale -$1.67M -5K -100% $333.00 0 22 Oct 2021 Direct F1
transaction MRNA Common Stock Options Exercise $2.53K +178 $14.22* 178 25 Oct 2021 Direct F1
transaction MRNA Common Stock Options Exercise $61.1K +5K +2808.99% $12.21* 5.18K 25 Oct 2021 Direct F1
transaction MRNA Common Stock Options Exercise $120K +9.82K +189.69% $12.21* 15K 25 Oct 2021 Direct F1
transaction MRNA Common Stock Sale -$4.91M -15K -100% $327.36 0 25 Oct 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -3.03% $0.00 160K 22 Oct 2021 Common Stock 5K $12.21 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -178 -0.26% $0.00 68.6K 25 Oct 2021 Common Stock 178 $14.22 Direct F1, F3
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -3.13% $0.00 155K 25 Oct 2021 Common Stock 5K $12.21 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -9.82K -6.34% $0.00 145K 25 Oct 2021 Common Stock 9.82K $12.21 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021.
F2 This option is fully vested and exercisable.
F3 25% of this option will vest and become exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.

Remarks:

Chief Technical Operations and Quality Officer